Syringe News and Research

RSS

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

Hospira's Nivestim receives Australian TGA approval

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration approval for its biosimilar filgrastim product, Nivestim.

27 Sep 2010

MAQUET enrolls first patient in OPTION trial

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with open vein harvesting methods.

23 Sep 2010

ConfiDisc Syringe Injection System granted U.S. patent

Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R).

21 Sep 2010

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.

21 Sep 2010

Revolutions Medical files suit against cyber smear campaign

Today, Revolutions Medical Corporation filed suit in Charleston County Common Pleas Court against Philip Maurice Hicks (a.k.a. "Marty Hicks) for libel. According to the complaint, Hicks, using the alias "tazmanian353" on two Internet message boards, is alleged to be waging a cyber smear campaign in an effort to destroy RMCP and its corporate management, particularly the company's chief executive officer, Rondald Wheet.

20 Sep 2010

Cytori Therapeutics releases schedule of fall 2010 and investor conferences

Cytori Therapeutics announced today its fall 2010 conference schedule.

13 Sep 2010

UCLA psychologist explains measure to overcome drug addiction

Millions of Americans suffer from severe addictions that can ruin lives and are extremely difficult to control. Nearly 2 million enter roughly 12,000 addiction treatment programs in the U.S. each year.

9 Sep 2010

RevMed secures contract with Medical Investment to produce fixed needle safety syringe

RevMed has secured a binding 5 Year contract to produce 5M syringes/month of its 3mL fixed needle safety syringe with Medical Investment Group, LLC (MIG). MIG, a Massachusetts Limited Liability Company, will fulfill this obligation through its relationship with an internationally certified global medical device manufacturer.

7 Sep 2010

Revolutions Medical signs Letter of Intent for manufacturing RevVac Safety Syringes

Revolutions Medical signs Letter of Intent today with Medical Investment Group, LLC (MIG) for the Manufacturing of the RevVac Safety Syringe. The final terms are expected to be completed in definitive documents between the parties no later than September 17th, 2010.

4 Sep 2010

Unitract Tuberculin syringe clears FDA 510k market clearance

Unilife Corporation, today announced that its Unitract Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).

2 Sep 2010

Unilife Corporation 2010 fourth quarter revenue increases to $2.7 million

Unilife Corporation today announced preliminary financial results for the fourth quarter and fiscal year ended June 30, 2010.

31 Aug 2010

Revolutions Medical seeks due recognition for RevVac vacuum operated auto retractable safety syringe

Revolutions Medical Corporation has notified the MDEA that there had been an error in awarding the Free Vac syringe the 2010 Medical Design Excellence Award when in fact Free Vac misrepresented ownership of the syringe. The syringe was actually Revolutions Medical Corporation's RevVac auto retractable safety syringe.

30 Aug 2010

DTC grants eligibility status to Medisafe 1 Technologies

Medisafe 1 Technologies Corp., a developer of a U.S. patented technology that physically prevents unauthorized administration of prescription medications, announced today that the company has been granted eligibility status by the Depository Trust Company. The DTC provides banks, brokerage firms and other institutions with an efficient means of moving securities and settling trades electronically.

26 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion for RELISTOR (methylnaltrexone bromide) subcutaneous injection in pre-filled syringes.

7 Aug 2010

Kaiser Family Foundation/CSIS forum reviews AIDS 2010, looks ahead to AIDS 2012

Last month's 18th International AIDS Conference-AIDS 2010 in Vienna, Austria, will be remembered as the first since the global economic downturn, the growing recognition of treatment as part of prevention and a focus on the importance of human rights, HIV/AIDS experts said Thursday during a panel discussion in Washington, D.C. A webcast of the event is available online.

6 Aug 2010

AMRI second-quarter adjusted EPS increases to $0.06

AMRI today reported financial and operating results for the second quarter ended June 30, 2010.

5 Aug 2010

ICU Medical's Neutron Neutral-Pressure Needleless Connector receives FDA clearance

ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in vascular therapy applications, today confirmed that it has received FDA 510-k clearance for the Neutron™ Neutral-Pressure Needleless Connector.

4 Aug 2010